Loading data for GALD.SW — first visit, this takes a few seconds.
Galderma Group AG (GALD.SW)
Swiss: GALD.SW
· 即時價格 · USD
167.90
-3.05 (-1.78%)
收盤價： Aug 31, 2026, 3:31 PM
股價、關鍵數字和最新消息，都在這一頁。
Galderma Group AG（GALD.SW）股價、分析與資料
無可用資料
| 買價 | 0 |
| 市值 | 39.2B |
| 營收 (ttm) | 5.92B |
| 淨利（ttm） | 863M |
| -0.10 | |
| 2.94 | |
| 57.11 | |
| 31.22 | |
| P/B (ttm) | 5.93 |
| P/S (ttm) | 6.61 |
| 財報日期 | Mar 4, 2027 |
| 賣價 | 0 |
| 成交量 | 604,917 |
| 20 日平均成交量 | 410,773 |
| 開盤價 | 170.25 |
| 前收盤價 | 170.95 |
| 當日區間 | 167.40 - 170.30 |
| 52 週範圍 | 130.20 - 188.25 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | $0.35 (0.20%) |
| 除息日 | Apr 24, 2026 |
關於 GALD.SW
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix...
完整的公司簡介財報驚奇
Galderma 已於 Invalid Date 公布季度財報：
- 營收為 n/a 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 低於預期 , 年增 NaN% 成長.
第 1 頁，共 2 頁